Interleukin-6 reduces cartilage destruction during experimental arthritis: A study in interleukin-6-deficient mice

American Journal of Pathology

Volumn 151, Issue 1, 1997, Pages 177-191

  Van de Loo, Fons A J ^a   Kuiper, Sandra ^a   Van Enckevort, Frank H J ^a   Arntz, Onno J ^a   Van den Berg, Wim B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 6; NITRIC OXIDE; PERTECHNETIC ACID TC 99M; PROTEOGLYCAN; TUMOR NECROSIS FACTOR; ZYMOSAN;

ACUTE PHASE RESPONSE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CARTILAGE CELL; CARTILAGE DEGENERATION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; GLYCOSYLATION; HISTOLOGY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RADIOIMMUNOASSAY; SIGNAL TRANSDUCTION; SYNOVIAL FLUID;

ANIMALS; ARTHRITIS; CARTILAGE, ARTICULAR; CORTICOSTERONE; CYTOKINES; INJECTIONS, INTRA-ARTICULAR; INTERLEUKIN-6; KNEE JOINT; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; OSTEOGENESIS; PROTEOGLYCANS; ZYMOSAN;

EID: 0030794222     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Lotz M: Interleukin-6. Cancer Invest 1993, 11:732-742
2. Barton BE: The biological effects of interleukin-6. Med Res Rev 1996, 16:87-109
3. Kishimoto T, Akira S, Taga T: Interleukin-6 and its receptor: a paradigm for cytokines. Science 1992, 258:593-597
4. Van Leeuwen MA, Westra J, Limburg PC, van Riel PLCM, van Rijswijk MH: Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid. Ann Rheum Dis 1995, 54:33-38
5. Hermann E, Fleischer B, Mayet WJ, Poralla T, Meyer zum Büschenfelde KH: Correlation of synovial fluid interleukin-6 (IL-6) activities with IgG concentrations in patients with inflammatory joint disease and osteoarthritis. Clin Exp Rheumatol 1989, 7:411-414
6. Waage A, Kaufmann C, Espevik T, Husby G: Interleukin-6 in synovial fluid from patients with arthritis. Clin Immunol Immunopathol 1989, 50:394-398
7. Brozik M, Rosztócky I, Merétey K, Bálint G, Gaál M, Balogh Z, Bart M, Mituszova M, Velics V, Falus A: Interleukin 6 levels in synovial fluids of patients with different arthritides: correlation with local IgM rheumatoid factor and systemic acute phase protein production. J Rheumatol 1992, 19:63-68
8. Holt I, Cooper RG, Hopkins SJ: Relationships between local inflammation, interleukin-6 concentrations and the acute phase protein response in arthritis patients. Eur J Clin Invest 1991, 21:479-484
9. Rosenbaum JT, Cugnini R, Tara DC, Hefeneider S, Ansel JC: Production and modulation of interleukin 6 synthesis by synoviocytes derived from patients with arthritic disease. Ann Rheum Dis 1992, 51:198-202
10. Wood NC, Symons JA, Dickens E, Duff GW: In situ hybridization of IL-6 in rheumatoid arthritis. Clin Exp Immunol 1992, 87:183-189
11. Guerne PA, Zuraw BL, Carson DA, Lotz M: Synovium as a source of interleukin 6 in vitro: contribution to local and systemic manifestations of arthritis. J Clin Invest 1989, 83:585-592
12. Bender S, Haubeck HD, van de Leur E, Dufhues G, Schiel X, Lauwerijns J, Greiling H, Heinrich PC: Interleukin-1β induces synthesis and secretion of interleukin-6 in human chondrocytes. FEBS Lett 1990, 263:321-324
13. Guerne PA, Carson DA, Lotz M: IL-6 production by human articular chondrocytes: modulation of its synthesis by cytokines, growth factors, and hormones in vitro. J Immunol 1990, 144:499-505
14. Akira S, Hirano T, Taga T, Kishimoto T: Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J 1990, 4:2860-2867
15. Wolvekamp MCJ, Marquet RL: Interleukin-6: historical background, genetics and biological significance. Immunol Lett 1990, 24:1-10
16. Gauldie J, Richards C, Harnish D, Lansdrop P, Baumann H: Interferon β2/B-ceil stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987, 84:7251-7255
17. Heinrich PC, Castell JV, Andus T: Interleukin-6 and the acute phase response. Biochem J 1990, 265:621-636
18. van Leeuwen MA, Westra J, Limburg PC, van Riel PLCM, van Rijswijk MH: Clinical significance of interleukin-6 measurements in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study. Ann Rheum Dis 1995, 54:674-677
19. Riedy MC, Steward CC: Inhibitory role of interleukin-6 in macrophage proliferation. J Leukocyte Biol 1992, 52:125-127
20. Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K, Iwamatsu A, Tsunasawa S, Sakiyama F, Matsui H, Takahara Y, Taniguchi T, Kishimoto T: Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986, 324:73-76
21. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW: Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994, 83:113-118
22. Ito A, Itoh Y, Sasaguri Y, Morimatsu M, Mori Y: Effects of interleukin-6 on the metabolism of connective tissue components in rheumatoid synovial fibroblasts. Arthritis Rheum 1992, 35:1197-1201
23. Aderka D, Le J, Vilcek J: IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol 1989, 143:3517-3523
24. De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A: Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991, 34:1158-1163
25. van de Loo AAJ, Joosten LAB, van Lent PLEM, Arntz OJ, van den Berg WB: Role of interleukin-1, tumor necrosis factor α and interleukin-6 in cartilage proteoglycan metabolism and destruction: effect of in situ cytokine blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995, 38:164-172
26. Van Lent PLEM, van den Berg WB, Schalkwijk J, van de Putte LBA, van den Bersselaar L: The impact of protein size and charge on its retention in articular cartilage. J Rheumatol 1987, 14:789-805
27. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bleuthmann H, Köhler G: Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994, 368:339-341
28. Ramsay AJ, Husband AJ, Ramshaw IA, Bao S, Matthaei KI, Koehler G, Kopf M: The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 1994, 264:561-563
29. Libert C, Takahashi N, Cauwels A, Brouckaert P, Bleuthmann H, Fiers W: Response of interleukin-6-deficient mice to tumor necrosis factor-induced metabolic changes and lethality. Eur J Immunol 1994, 24:2237-2242
30. Bleuthmann H, Rothe J, Schultze N, Tkachuk M, Koebel P: Establishment of the role of IL-6 and TNF receptor 1 using gene knockout mice. J Leukocyte Biol 1994, 56:565-570
31. Chai Z, Gatti S, Toniatti C, Poli V, Bartfai T: Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1β: a study on IL-6-deficient mice. J Exp Med 1996, 183:311-316
32. Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G, Rodan GA, Costantini F: Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 1994, 13:1189-1196
33. Bromander AK, Ekman L, Kopf M, Nedrud JG, Lycke NY: IL-6-deficient mice exhibit normal mucosal IgA responses to local immunization and Helicobacter felis infection. J Immunol 1996, 156:4290-4297
34. Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, Faggioni R, Fantuzzi G, Ghezzi P, Poli V: Defective inflammatory response in interleukin-6-deficient mice. J Exp Med 1994, 180:1243-1250
35. Keystone EC, Schorlemmer HU, Pope C, Allison AC: Zymosan-induced arthritis: a model of chronic proliferative arthritis following activation of the alternative pathway of complement. Arthritis Rheum 1977, 20:1396-1401
36. 3 U/ml of interleukin-2. J Immunol Methods 1987, 99:7-11
37. Drenth JPH, van Uum SHM, van Deuren M, Pesman GJ, van der Ven-Jongekrijg J, van der Meer JWM: Endurance run increases circulating IL-6 and IL-1ra but down regulates ex vivo TNF-α and IL-1β production. J Appl Physiol 1995, 79:1497-1503
38. Sweep CGJ, van der Meer MJM, Hermus ARMM, Smals AGH, van der Meer JWM, Pesman GJ, Willemsen SJ, Benraad TJ, Kloppenborg PWC: Chronic stimulation of the pituitary-adrenal axis in rats by interleukin-1βinfusion: in vivo and in vitro studies. Endocrinology 1992, 130:1153-1164
39. van den Berg WB, Kruijsen MWM, van de Putte LBA: The mouse patella assay: an easy method of quantitating articular cartilage chondrocyte function in vivo and in vitro. Rheumatol Int 1982, 1:165-169
40. 3H-acetate. Rheumatol Int 1987, 6:273-281
41. Asmuth EJU, Maessen JG, van der Linden CJ, Buurman WA: Tumour necrosis factor α (TNF-α) and interleukin 6 in a zymosan-induced shock model. Scand J Immunol 1990, 32:313-319
42. Dawson J, Rordorf-Adam C, Geiger T, Towbin H, Kunz S, Nguyen H, Zingel O, Chaplin D, Vosbeck K: Interleukin-1 (IL-1) production in a mouse tissue chamber model of inflammation. I. Development and initial characterisation of the model. Agents Actions 1993, 38:247-254
43. Erdö F, Török K, Székely JI: Measurement of interleukin-1 liberation in zymosan air-pouch exudate in mice. Agents Actions 1994, 41:93-95
44. Van de Loo FAJ, Arntz OJ, van den Berg WB: Effect of interleukin-1 and leukemia inhibitory factor on chondrocyte metabolism in articular cartilage from normal and interleukin-6-deficient mice: role of nitric-oxide and IL-6 in the suppression of proteoglycan synthesis. Cytokine 1997 (in press)
45. Williams RO, Feldmann M, Maini RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen- induced arthritis. Proc Natl Acad Sci USA 1992, 89:9784-9788
46. Wooley PH, Dutcher J, Widmer MB, Gillis S: Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993, 151:6602-6607
47. Wooley PH, Whalen JD, Chapman DL Berger AE, Richard KA, Aspar DG, Staite ND: The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 1993, 36:1305-1314
48. Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB: Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum 1996, 39:797-809
49. van de Loo AAJ, Arntz OJ, van Lent PLEM, Jacobs MJM, van den Berg WB: Role of interleukin-1 in antigen-induced exacerbations of murine arthritis. Am J Pathol 1995, 146:239-149
50. Perretti M, Solito E, Parente L: Evidence that endogenous interleukin-1 is involved in leukocyte migration in acute experimental inflammation in rats and mice. Agents Actions 1992, 35:71-78
51. Vladutiu AO: Role of nitric oxide in autoimmunity. Clin Immunol Immunopathol 1995, 76:1-11
52. McCartney-Francis N, Allen JB, Mizel DE, Albina JE, Wie QW, Nathan CF, Wahl SM: Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med 1993, 178:749-754
53. Stefanovic-Racic M, Meyers K, Meschter C, Coffey JW, Hoffmann RA, Evans CH: N-Monomethyl arginine, an inhibitor of nitric oxide synthase, suppresses the development of adjuvant arthritis in rats. Arthritis Rheum 1994, 37:1062-1069
54. G-monomethyl-L-arginine. J Exp Med 1994, 179:651-660
55. Biffl WL, Moore EE, Moore FA, Barnett CC: Interleukin-6 suppression of neutrophil apoptosis is neutrophil concentration dependent. J Leukocyte Biol 1995, 58:582-584
56. Shingu M, Isayama T, Yasutake C, Naono T, Nobunaga M, Tomari K, Horie K, Goto Y: Role of oxygen radicals and IL-6 in IL-1-dependent cartilage matrix degradation. Inflammation 1994, 18:613-623
57. Baumann H, Gauldie J: The acute phase response. Immunol Today 1994, 15:74-80
58. Nemoto O, Yamada H, Mukaida M, Shimmei M: Stimulation of TIMP-1 production by oncostatin M in human articular cartilage. Arthritis Rheum 1996, 39:560-566
59. Yeh LA, Augustine AJ, Lee P, Riviere LR, Sheldon A: Interleukin-4, an inhibitor of cartilage breakdown in bovine cartilage explants. J Rheumatol 1995, 22:1740-1749
60. van Roon JA, van Roy JL, Gmelig-Meyling FH, Lafeber FP, Bijlsma JW: Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum 1996, 39:829-835
61. Joosten LAB, Lubberst E, Durez P, Helsen MMA, Jacobs MJM, Goldman M, van den Berg: Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis: protective role of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997 (in press)
62. Verschure PJ, Joosten LAB, van der Kraan PM, van den Berg WB: Responsiveness of articular cartilage from normal and inflamed mouse knee joints to various growth factors. Ann Rheum Dis 1994, 53:455-460
63. Tyler JA: Insulin like growth factor 1 can decrease cartilage degradation and promote synthesis of proteoglycan in cartilage exposed to cytokines. Biochem J 1989, 260:543-548
64. Flechtenmacher J, Much K, Thonar EJMA, Mollenhauser JA, Davies SR, Schmid TM, Puhl W, Sampath TK, Aydelotte MB, Kuettner KE: Recombinant human osteogenic protein 1 is a potent stimulator of the synthesis of cartilage proteoglycans and collagens by human articular chondrocytes. Arthritis Rheum 1996, 39:1896-1904
65. Luyten FP, Chen P, Paralkar V, Reddi AH: Recombinant bone morphogenetic protein-4, transforming growth factor-β-1, and activin A enhance the cartilage phenotype of articular chondrocytes in vitro. Exp Cell Res 1994, 210:224-229
66. Van Osch GJVM, van Valburg AA, van der Kraan PM, van den Berg WB: The relation between cartilage damage and osteophyte formation in a murine model for osteoarthritis in the knee. Rheumatol Int 1996, 16:115-119
67. Van der Kraan PM, Vitters EL, van Beuningen HM, van de Putte BA, van den Berg WB: Degenerative knee joint lesions in mice after a single intra-articular collagenase injection: a new model of osteoarthritis. J Exp Pathol 1990, 71:19-31
68. Schalkwijk J, van den Berg WB, van de Putte LBA, Joosten LAB, van der Sluis M: Effects of experimental joint inflammation on bone: marrow and periarticular bone: a study of two types of arthritis, using variable degrees of inflammation. Br J Exp Pathol 1985, 66:435-444
69. Van Beuningen HM, van der Kraan PM, Arntz OJ, van den Berg WB: Transforming growth factor-β1 stimulates articular chondrocyte proteoglycan synthesis and induces osteophyte formation in the murine knee joint. Lab Invest 1994, 95:237-243
70. Van Beuningen HM, van der Kraan PM, Arntz OJ, van den Berg WB: In vivo protection against interleukin-1-induced articular cartilage damage by transforming growth factor β1: age related differences. Ann Rheum Dis 1994, 53:593-600
71. Villinger PM, Kusari AB, ten Dijke P, Lotz M: IL-1β and IL-6 selectively induce transforming growth factor-β in human articular chondrocytes. J Immunol 1993, 151:3337-3344
72. Zhou D, Munster A, Winchurch RA: Pathologic concentrations of interleukin 6 inhibit T cell responses via induction of activation of TGF-β. FASEB J 1991, 5:2582-2585
73. Zhou D, Munster AM, Winchurch RA: Inhibitory effects of interleukin 6 on immunity: possible implications in burn patients. Arch Surg 1992, 127:65-69
74. Glansbeek HL, van Beuningen HM, Vitters EL, Morris EA, van der Kraan PK, van den Berg WB: Bone morphogenetic protein-2 stimulates articular cartilage proteoglycan synthesis in vivo but is not able to counteract interleukin-1α effects on proteoglycan synthesis and content. Arthritis Rheum 1997 (in press)